相关实验视频

Updated: Jan 9, 2026

Pulmonary Embolism III: Nursing Management

Pulmonary Embolism III: Nursing Management

Published on: June 19, 2025

miR-181a是T细胞敏感性和选择的内在调节器

Qi-Jing Li¹, Jacqueline Chau, Peter J R Ebert

¹Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.

|March 27, 2007

概括

微RNA-181a (miR-181a) 起作用为风静止剂,在发育过程中微调T细胞对抗原的敏感性. 它的表达水平极大地影响T细胞选择,免疫力和耐受性.

科学领域:

免疫学免疫学免疫学
分子生物学分子生物学
发展生物学发展生物学

背景情况:

对抗原的T细胞敏感性对于免疫反应和自我耐受性至关重要.
在成熟过程中调节T细胞抗原敏感性的内在机制尚未完全理解.
微RNAs (miRNAs) 是已知的基因表达的调节者,在免疫细胞发育中发挥作用.

研究的目的:

研究微RNA-181a (miR-181a) 在调节T细胞对抗原敏感性的作用.
阐明miR-181a调节T细胞受体信号的分子机制.
确定miR-181a对T细胞发育,选择和功能的影响.

主要方法:

在不成熟和成熟的T细胞中调节miR-181a表达.
评估T细胞对各种抗原的敏感性,包括激动剂和对抗剂.
分析T细胞受体信号通路,包括酸酶活性和酸化水平.
对T细胞阳性和阴性选择过程的评估.

主要成果:

在成熟的T细胞中增加miR-181a表达增强了抗原敏感性.
在不成熟的T细胞中抑制miR-181a降低了敏感性和受损的阳性/阴性选择.
miR-181a通过降低酸酶的调节来调节T细胞敏感性,降低信号值.
miR-181a使对抗性的识别成为激动剂.

结论:

在发育过程中,miR-181a 作为一种内在的静脉静止剂,控制T细胞抗原的敏感性.
定量调节miR-181a对于适当的T细胞选择,免疫力和耐受性至关重要.
miR-181a在调节酸酶活性中的作用影响T细胞受体信号值.

更多相关视频

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Published on: June 19, 2025

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

Published on: June 19, 2025

相关概念视频

Pulmonary Embolism III: Nursing Management

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Pneumothorax-II

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation